Dyne Therapeutics Q1 EPS $(0.69) Down From $(0.50) YoY

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.69) per share. This is a 38 percent decrease over losses of $(0.50) per share from the same period last year.

byBenzinga Newsdesk

May 2, 2022

1 minute read

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.69) per share. This is a 38 percent decrease over losses of $(0.50) per share from the same period last year.

Morgan Stanley Maintains Equal-Weight on PPL, Raises Price Target to $34

By Benzinga Newsdesk

Today, 11:29 PM

Morgan Stanley analyst Stephen Byrd maintains PPL (NYSE:PPL) with a Equal-Weight and raises the price target from $32 to $34.

PPL

Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock

By Vandana Singh

Today, 11:29 PM

HC Wainwright initiated coverage of Lyell Immunopharma Inc (NASDAQ:LYEL) with a Buy rating and a price target of $12 per share. Lyell…

LYEL

PaySign Q1 EPS $(0.01) Up From $(0.03) YoY, Sales $8.22M Beat $8.22M Estimate

By Benzinga Newsdesk

Today, 11:29 PM

PaySign (NASDAQ:PAYS) reported quarterly losses of $(0.01) per share. This is a 66.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $8.22

PAYS

Larry Summers Warns Of A ‘Dangerous Drop-Off’ In Economic Activity If Fed Hits The Brakes “Very, Very Hard’

By Shanthi Rexaline

Today, 11:29 PM

The past week’s strong data points got experts talking about “higher rates for longer.” Former Treasury Secretary Larry Summers offered his take on the data and the near-term trajectory of the Fed funds rat

SPY

Dyne Therapeutics Q1 EPS $(0.69) Down From $(0.50) YoY

Related Posts

Morgan Stanley Maintains Equal-Weight on PPL, Raises Price Target to $34

Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock

PaySign Q1 EPS $(0.01) Up From $(0.03) YoY, Sales $8.22M Beat $8.22M Estimate

Larry Summers Warns Of A ‘Dangerous Drop-Off’ In Economic Activity If Fed Hits The Brakes “Very, Very Hard’